PTH Assays and Their Clinical Significance

  • Pierre D’AmourEmail author


PTH assays have been used to detect several conditions including hypoparathyroidism, hyperparathyroidism, hypercalcemia of malignancy, vitamin D deficiency, and renal failure. First-generation PTH assays had difficulty in the differentiation of these conditions. Second-generation PTH assays improved these diagnostics, while third-generation PTH assays behave similarly to second-generation PTH assays.


Hypoparathyroidism Hyperparathyroidism Renal failure Hypercalcemia of malignancy Vitamin D deficiency 


  1. 1.
    Berson SA, Yalow RS, Aurbach GD, Potts JT (1963) Immunoassay of bovine and human parathyroid hormone. Proc Natl Acad Sci U S A 49:613–617CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT Jr, Segre GV (1987) Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364–1367PubMedGoogle Scholar
  3. 3.
    John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H (1999) A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287–4290CrossRefPubMedGoogle Scholar
  4. 4.
    Segre GV, Tregear G, Potts JT Jr (1975) Development and application of sequence-specific radioimmunoassay for analysis of the metabolism of parathyroid hormone. In: O’Malley BW, Hardman JG (eds) Methods on enzymology, vol 37. Academic, New York, pp 38–66Google Scholar
  5. 5.
    D’Amour P, Labelle F, Lazure C (1984) Comparison of four different carboxylterminal tracers in a radioimmunoassay specific to the 68–84 region of human parathyroid hormone. J Immunoassay 5:183–204CrossRefPubMedGoogle Scholar
  6. 6.
    Berson SA, Yalow RS (1968) Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab 28:1037–1047CrossRefPubMedGoogle Scholar
  7. 7.
    D’Amour P, Labelle F, Lecavalier L, Plourde V, Harvey D (1986) Influence of serum Ca concentration on circulating molecular forms of PTH in three species. Am J Physiol 251:E680–E687PubMedGoogle Scholar
  8. 8.
    Segre BV, D’Amour P, Potts JT (1976) Metabolism of radioiodinated bovine parathyroid hormone in the rat. Endocrinology 99:1645–1652CrossRefPubMedGoogle Scholar
  9. 9.
    Zhang CX, Weber BV, Thammavong J, Grover TA, Wells DS (2006) Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem 78:1636–1643CrossRefPubMedGoogle Scholar
  10. 10.
    Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barré M, D’Amour P (1996) Accumulation of a non-(1–84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 81:3923–3929PubMedGoogle Scholar
  11. 11.
    D’Amour P, Brossard JH, Rousseau L, Nguyen-Yamamoto L, Nassif E, Lazure C, Gauthier D, Lavigne JR, Zahradnik RJ (2005) Structure of non-(1–84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 68:998–1007CrossRefPubMedGoogle Scholar
  12. 12.
    D’Amour P, Räkel A, Brossard JH, Rousseau L, Albert C, Cantor T (2006) Acute regulation of circulating parathyroid hormone (PTH) molecular forms by calcium: utility of PTH fragments/PTH(1–84) ratios derived from three generations of PTH assays. J Clin Endocrinol Metab 91:283–289CrossRefPubMedGoogle Scholar
  13. 13.
    D’Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T (2003) Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1–84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 49:2037–2044CrossRefPubMedGoogle Scholar
  14. 14.
    Rabbani SA, Kremer R, Bennett HP, Goltzman D (1984) Phosphorylation of parathyroid hormone by human and bovine parathyroid glands. J Biol Chem 259:2949–2955PubMedGoogle Scholar
  15. 15.
    Räkel A, Brossard JH, Patenaude JV, Albert C, Nassif E, Cantor T, Rousseau L, D’Amour P (2005) Overproduction of an amino-terminal form of PTH distinct from human PTH(1–84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol (Oxf) 62:721–727CrossRefGoogle Scholar
  16. 16.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Fujii H, Fukagawa M (2005) Normalization of reversed bio-intact-PTH(1–84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism. Clin Nephrol 64:69–72CrossRefPubMedGoogle Scholar
  17. 17.
    Arakawa T, D’Amour P, Rousseau L, Brossard JH, Sakai M, Kasumoto H, Igaki N, Goto T, Cantor T, Fukagawa M (2006) Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. Clin J Am Soc Nephrol 1:525–531CrossRefPubMedGoogle Scholar
  18. 18.
    Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC (2006) Unexpected serum parathyroid hormone profiles in some patients with primary hyperparathyroidism. Clin Chem 52:757–760CrossRefPubMedGoogle Scholar
  19. 19.
    Rubin MR, Silverberg SJ, D’Amour P, Brossard JH, Rousseau L, Sliney J Jr, Cantor T, Bilezikian JP (2007) An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem 53:1470–1476CrossRefPubMedGoogle Scholar
  20. 20.
    Caron P, Maiza JC, Renaud C, Cormier C, Barres BH, Souberbielle JC (2009) High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 70:533–538CrossRefGoogle Scholar
  21. 21.
    Cavalier E, Daly AF, Betea D, Pruteanu-Apetrii PN, Delanaye P, Stubbs P, Bradwell AR, Chapelle JP, Beckers A (2010) The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 95:3745–3749CrossRefPubMedGoogle Scholar
  22. 22.
    D’Amour P, Segre GV, Roth SI, Potts JT Jr (1979) Analysis of parathyroid hormone and its fragments in rat tissues: chemical identification and microscopical localization. J Clin Invest 63:89–98CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, Gao P, Cantor T, D’Amour P (2002) Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 147:123–131CrossRefPubMedGoogle Scholar
  24. 24.
    Habener JF, Rosenblatt M, Potts JT Jr (1984) Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol Rev 64:985–1053PubMedGoogle Scholar
  25. 25.
    Silver J, Russell J, Sherwood LM (1985) Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci 82:4270–4273CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Kilav R, Silver J, Naveh-Many T (2001) A conserved cis-acting element in the parathyroid hormone 3′-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate. J Biol Chem 276:8727–8733CrossRefPubMedGoogle Scholar
  27. 27.
    Wecksler WR, Ross FP, Mason RS, Posen S, Norman AW (1980) Biochemical properties of the 1 alpha, 25-dihydroxyvitamin D3 cytoplasmic receptors from human and chick parathyroid glands. Arch Biochem Biophys 201:95–103CrossRefPubMedGoogle Scholar
  28. 28.
    Setoguti T, Inoue Y, Shin M (1988) Electron-microscopic studies on the threshold value of calcium concentration for the release of storage granules and the acceleration of their degradation in the rat parathyroid gland. Cell Tissue Res 251:531–539CrossRefPubMedGoogle Scholar
  29. 29.
    Hashizume Y, Waguri S, Watanabe T, Kominami E, Uchiyama Y (1993) Cysteine proteinases in rat parathyroid cells with special reference to their correlation with parathyroid hormone (PTH) in storage granules. J Histochem Cytochem 41:273–282CrossRefPubMedGoogle Scholar
  30. 30.
    Bringhurst FR, Stern AM, Yotts M, Mizrahi N, Segre GV, Potts JT Jr (1989) Peripheral metabolism of [35S]parathyroid hormone in vivo: influence of alterations in calcium availability and parathyroid status. J Endocrinol 122:237–245CrossRefPubMedGoogle Scholar
  31. 31.
    Segre GV, D’Amour P, Hultman A, Potts JT Jr (1981) Effects of hepatectomy, nephrectomy, and nephrectomy/uremia on the metabolism of parathyroid hormone in the rat. J Clin Invest 67:439–448CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Mayer GP, Keaton JA, Hurst JG, Habener JF (1979) Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood. Endocrinology 104:1778–1784CrossRefPubMedGoogle Scholar
  33. 33.
    Mayer GP, Hurst JG (1978) Sigmoidal relationship between parathyroid hormone secretion rate and plasma calcium concentration in calves. Endocrinology 102:1036–1042CrossRefPubMedGoogle Scholar
  34. 34.
    Mayer GP, Habener JF, Potts JT Jr (1976) Parathyroid hormone secretion in vivo. Demonstration of a calcium-independent nonsuppressible component of secretion. J Clin Invest 57:678–683CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Cloutier M, D’Amour P, Gascon-Barré M, Hamel L (1990) Low calcium diet in dogs causes a greater increase in parathyroid function measured with an intact hormone than with a carboxylterminal assay. Bone Miner 9:179–188CrossRefPubMedGoogle Scholar
  36. 36.
    Cloutier M, Gascon-Barré M, D’Amour P (1992) Chronic adaptation of dog parathyroid function to a low-calcium-high-sodium-vitamin D-deficient diet. J Bone Miner Res 7:1021–1028CrossRefPubMedGoogle Scholar
  37. 37.
    Cloutier M, Gagnon Y, Gascon-Barré M, Brossard JH, D’Amour P (1997) Adaptation of parathyroid function to intravenous 1,25-dihydroxyvitamin D3 or partial parathyroidectomy in normal dogs. J Endocrinol 155:133–141CrossRefPubMedGoogle Scholar
  38. 38.
    Brossard JH, Whittom S, Lepage R, D’Amour P (1993) Carboxyl-terminal fragments of parathyroid hormone are not secreted preferentially in primary hyperparathyroidism as they are in other hypercalcemic conditions. J Clin Endocrinol Metab 77:413–419PubMedGoogle Scholar
  39. 39.
    Hannan FM, Thakker RV (2013) Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism. Best Pract Res Clin Endocrinol Metab 27:359–371CrossRefPubMedGoogle Scholar
  40. 40.
    D’Amour P, Weisnagel J, Brossard JH, Ste-Marie LG, Rousseau L, Lepage R (1998) Functional evidence for two types of parathyroid adenoma. Clin Endocrinol (Oxf) 48:593–601CrossRefGoogle Scholar
  41. 41.
    Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR (2005) Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 90:2122–2126CrossRefPubMedGoogle Scholar
  42. 42.
    Beyer TD, Chen EL, Nilubol N, Prinz RA, Solorzano CC (2007) Short-term outcomes of parathyroidectomy in patients with or without 25-hydroxy vitamin D insufficiency. J Surg Res 143:145–150CrossRefPubMedGoogle Scholar
  43. 43.
    Untch BR, Barfield ME, Dar M, Dixit D, Leight GS Jr, Olson JA Jr (2007) Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 142:1022–1026CrossRefPubMedGoogle Scholar
  44. 44.
    Silverberg SJ (2007) Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res 22:V100–V104CrossRefPubMedGoogle Scholar
  45. 45.
    Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB, Perrier ND (2008) Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 144:852–858CrossRefPubMedGoogle Scholar
  46. 46.
    Isidro ML, Ruano B (2009) Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 36:305–310CrossRefPubMedGoogle Scholar
  47. 47.
    Tucci JR (2009) Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol 161:189–193CrossRefPubMedGoogle Scholar
  48. 48.
    Wagner D, Xia Y, Hou R (2013) Safety of vitamin D replacement in patients with primary hyperparathyroidism and concomitant vitamin D deficiency. Endocr Pract 19:420–425CrossRefPubMedGoogle Scholar
  49. 49.
    Souberbielle JC, Bienaimé F, Cavalier E, Cormier C (2012) Vitamin D and primary hyperparathyroidism (PHPT). Ann Endocrinol 73:165–169CrossRefGoogle Scholar
  50. 50.
    Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, Talpos GB, Parfitt AM (2000) Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 85:1054–1058PubMedGoogle Scholar
  51. 51.
    Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L (2011) Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol 165:851–864CrossRefPubMedGoogle Scholar
  52. 52.
    Stein EM, Dempster DW, Udesky J, Zhou H, Bilezikian JP, Shane E, Silverberg SJ (2011) Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone 48:557–561CrossRefPubMedCentralPubMedGoogle Scholar
  53. 53.
    Kantorovich V, Gacad MA, Seeger LL, Adams JS (2000) Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 85:3541–3543PubMedGoogle Scholar
  54. 54.
    Laway BA, Goswami R, Singh N, Gupta N, Seith A (2006) Pattern of bone mineral density in patients with sporadic idiopathic hypoparathyroidism. Clin Endocrinol (Oxf) 64:405–409Google Scholar
  55. 55.
    Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney J Jr, Silverberg SJ, Bilezikian JP (2008) Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res 23:2018–2024CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    Abugassa S, Nordenström J, Eriksson S, Sjödén G (1993) Bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 76:1617–1621PubMedGoogle Scholar
  57. 57.
    Touliatos JS, Sebes JI, Hinton A, McCommon D, Karas JG, Palmieri GM (1995) Hypoparathyroidism counteracts risk factors for osteoporosis. Am J Med Sci 310:56–60CrossRefPubMedGoogle Scholar
  58. 58.
    Rubin MR, Dempster DW, Kohler T, Stauber M, Zhou H, Shane E, Nickolas T, Stein E, Sliney J Jr, Silverberg SJ, Bilezikian JP, Müller R (2010) Three dimensional cancellous bone structure in hypoparathyroidism. Bone 46:190–195CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Rubin MR, Dempster DW, Sliney J Jr, Zhou H, Nickolas TL, Stein EM, Dworakowski E, Dellabadia M, Ives R, McMahon DJ, Zhang C, Silverberg SJ, Shane E, Cremers S, Bilezikian JP (2011) PTH(1–84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res 26:2727–2736CrossRefPubMedCentralPubMedGoogle Scholar
  60. 60.
    Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L, Hypoparathyroid Study Group (2011) The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res 26:2358–2370CrossRefPubMedGoogle Scholar
  61. 61.
    Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28:2277–2285CrossRefPubMedGoogle Scholar
  62. 62.
    Cavicchi O, Piccin O, Caliceti U, Fernandez IJ, Bordonaro C, Saggese D, Ceroni AR (2008) Accuracy of PTH assay and corrected calcium in early prediction of hypoparathyroidism after thyroid surgery. Otolaryngol Head Neck Surg 138:594–600CrossRefPubMedGoogle Scholar
  63. 63.
    Ezzat WF, Fathey H, Fawaz S, El-Ashri A, Youssef T, Othman HB (2011) Intraoperative parathyroid hormone as an indicator for parathyroid gland preservation in thyroid surgery. Swiss Med Wkly 141:w13299PubMedGoogle Scholar
  64. 64.
    Nilubol N, Weisbrod AB, Weinstein LS, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E (2013) Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy. World J Surg 37:1966–1972CrossRefPubMedGoogle Scholar
  65. 65.
    Cayo AK, Yen TW, Misustin SM, Wall K, Wilson SD, Evans DB, Wang TS (2012) Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study. Surgery 152:1059–1067CrossRefPubMedGoogle Scholar
  66. 66.
    Borot S, Lapierre V, Carnaille B, Goudet P, Penfornis A (2010) Results of cryopreserved parathyroid autografts: a retrospective multicenter study. Surgery 147:529–535CrossRefPubMedGoogle Scholar
  67. 67.
    Cohen MS, Dilley WG, Wells SA Jr, Moley JF, Doherty GM, Sicard GA, Skinner MA, Norton JA, DeBenedetti MK, Lairmore TC (2005) Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery 138(6):1033–1040; discussion 1040–1041CrossRefPubMedGoogle Scholar
  68. 68.
    Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr (2008) Effects of once versus twice-daily parathyroid hormone 1–34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 93:3389–3395CrossRefPubMedCentralPubMedGoogle Scholar
  69. 69.
    Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr (2010) Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1–34 versus calcitriol and calcium. J Clin Endocrinol Metab 95:2680–2688CrossRefPubMedCentralPubMedGoogle Scholar
  70. 70.
    Gafni RI, Brahim JS, Andreopoulou P, Bhattacharyya N, Kelly MH, Brillante BA, Reynolds JC, Zhou H, Dempster DW, Collins MT (2012) Daily parathyroid hormone 1–34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Miner Res 27:1811–1820CrossRefPubMedCentralPubMedGoogle Scholar
  71. 71.
    Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS, Cutler GB Jr (2012) Synthetic human parathyroid hormone 1–34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab 97:391–399CrossRefPubMedCentralPubMedGoogle Scholar
  72. 72.
    Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP (2010) Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int 21:1927–1934CrossRefPubMedCentralPubMedGoogle Scholar
  73. 73.
    Cusano NE, Rubin MR, McMahon DJ, Zhang C, Ives R, Tulley A, Sliney J Jr, Cremers SC, Bilezikian JP (2013) Therapy of hypoparathyroidism with PTH(1–84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab 98:137–144CrossRefPubMedCentralPubMedGoogle Scholar
  74. 74.
    Rejnmark L, Sikjaer T, Underbjerg L, Mosekilde L (2013) PTH replacement therapy of hypoparathyroidism. Osteoporos Int 24:1529–1536CrossRefPubMedGoogle Scholar
  75. 75.
    Sikjaer T, Amstrup AK, Rolighed L, Kjaer SG, Mosekilde L, Rejnmark L (2013) PTH(1–84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res 28:2232–2243CrossRefPubMedGoogle Scholar
  76. 76.
    Benson RC Jr, Riggs BL, Pickard BM, Arnaud CD (1974) Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease. Am J Med 56:821–826CrossRefPubMedGoogle Scholar
  77. 77.
    Lufkin EG, Kao PC, Heath H 3rd (1987) Parathyroid hormone radioimmunoassays in the differential diagnosis of hypercalcemia due to primary hyperparathyroidism or malignancy. Ann Intern Med 106:559–560CrossRefPubMedGoogle Scholar
  78. 78.
    Kawahara M, Iwasaki Y, Sakaguchi K, Taguchi T, Nishiyama M, Nigawara T, Tsugita M, Kambayashi M, Suda T, Hashimoto K (2008) Predominant role of 25OHD in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. Life Sci 82:677–683CrossRefPubMedGoogle Scholar
  79. 79.
    Björkman M, Sorva A, Tilvis R (2009) Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. Arch Gerontol Geriatr 48:160–166CrossRefPubMedGoogle Scholar
  80. 80.
    Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501CrossRefPubMedGoogle Scholar
  81. 81.
    Björkman M, Sorva A, Risteli J, Tilvis R (2007) Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients. Age Ageing 37:25–31CrossRefPubMedGoogle Scholar
  82. 82.
    Vieth R, Ladak Y, Walfish PG (2003) Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 88:185–191CrossRefPubMedGoogle Scholar
  83. 83.
    Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, D’Amour P (2000) Influence of glomerular filtration rate on non-(1–84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 46:697–703PubMedGoogle Scholar
  84. 84.
    Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH (2001) Improved assessment of bone turnover by the PTH-(1–84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460–1468CrossRefPubMedGoogle Scholar
  85. 85.
    Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Jüppner H (2003) Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63:1801–1808CrossRefPubMedGoogle Scholar
  86. 86.
    Koller H, Zitt E, Staudacher G, Neyer U, Mayer G, Rosenkranz AR (2004) Variable parathyroid hormone(1–84)/carboxylterminal PTH ratios detected by 4 novel parathyroid hormone assays. Clin Nephrol 61:337–343CrossRefPubMedGoogle Scholar
  87. 87.
    Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A (2000) A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753–761PubMedGoogle Scholar
  88. 88.
    D’Amour P (2008) Lessons from a second- and third-generation parathyroid hormone assays in renal failure patients. J Endocrinol Invest 31:459–462CrossRefPubMedGoogle Scholar
  89. 89.
    National Kidney Foundation (2003) KIDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–S202Google Scholar
  90. 90.
    Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P (2006) Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 70:345–350CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2015

Authors and Affiliations

  1. 1.Department of MedicineCHUM Saint-Luc HospitalMontréalCanada

Personalised recommendations